Fig. 3.
Indirect immunofluorescence analysis of the antigenic profile of SGI-110-treated Mel 275 melanoma cells. a Mel 275 melanoma cells untreated (solid line) and treated with 1 μM SGI-110 (dotted line) or with 1 μM 5-AZA-CdR (dashed line) were sequentially incubated with the isotype-matched mouse Ig, the anti-HLA class I mAb W6/32, the anti-HLA-A2 mAb BB7.2 or the anti-ICAM-1 mAb 84H10, and with FITC-conjugated F(ab′)2 fragments of rabbit anti-mouse Ig. Cells were then analyzed by flow cytometry. b Paraformaldehyde-fixed and permeabilized Mel 275 melanoma cells, either untreated or treated with 1 μM SGI-110, were sequentially incubated with the anti-MAGE-A1 mAb MA454, the anti-NY-ESO-1 mAb D8.38, or the anti-gp100 mAb HMB-45, and with FITC-conjugated F(ab′)2 fragments of rabbit anti-mouse Ig, followed by flow cytometry. The reported numbers represent the percentage of TAA-positive cells in upper and lower right quadrants. Data are representative of three independent experiments